Diagnostics Co. Alere To Acquire EScreen For $270M

Law360, New York (February 28, 2012, 1:27 PM EST) -- Health management company Alere Inc. has agreed to purchase toxicology screening company eScreen Inc. for $270 million in a move to strengthen its position in the diagnostics market, Alere announced Tuesday.

Alere, headquartered in Waltham, Mass., has signed a binding agreement to buy Kansas-based eScreen — which produces employee drug-screening tools — for $270 million with possible additional payments of up to $70 million based on certain conditions, Alere said.

Subject to customary closing regulations, the deal is expected to close within 45 days, Alere said....
To view the full article, register now.